| Duke Clinical Research Institute |
| Overview | Devices Unit Research Track |
Cardiovascular Devices Unit Research Track
Duke Clinical Research Institute
Faculty
Mitchell W. Krucoff, MD, Director
Vic Hasselblad, PhD, Senior Statistician
Vic Hasselblad, PhD, Senior Statistician
Circulatory and
cardiovascular devices are one of the fastest moving, highest impact areas of
medical therapeutics. Blending regulatory, academic and industry priorities
into optimal clinical trial designs provides challenging opportunities for
creativity and teamwork.
The DCRI Cardiovascular
Devices Unit is a dedicated cross-section of clinical and statistical faculty
and operational staff focused on the design, execution and reporting of
national and global clinical trials testing novel cardiovascular devices. Our activities involve pre- and
post-market new device assessment from strategic planning, protocol development
and statistical analysis plan through site selection, study initiation and data
analysis and reporting. New percutaneous drug eluting stents, distal protection
systems, thrombectomy, atherectomy, photodynamic therapy, septal occluders and
valves represent unique therapeutic areas of application. In addition to these
therapeutic devices, invasive and implantable diagnostic devices detecting
vulnerable plaque or continuously monitoring intracardiac pressures represent
unique clinical trial opportunities and challenges.
Cardiovascular medicine fellows involved in the unit's research receive training and participate in trial design development,
learn regulatory process and requirements, statistical principles and work
directly with at least one entrepreneurial study sponsor.
Selected Publications:
-
- Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff MW, Gibbons RJ, Jones D, Lansky AJ, Mehran R, for the Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators; Distal Microcirulatory Protection During Percutaneous Coronary Intervention in Acute ST-segment Elevation Myocardial Infarction, JAMA 2005;293:1063-1072.
- Keriakes DJ, Kuntz RE, Mauri L, Krucoff MW; Surrogates, Substudies and Real Clinical Endpoints in Trials of Drug-Eluting Stents. JACC 2005; 45(8): 1206-1212.




DHTS WEB SERVICES